TABLE 2.
Significant SNPs for ER+ breast cancer
| rs73443365 | rs147106204 | |
|---|---|---|
| Gene | LATS2 | WWC1 |
| Major/minor alleles | A/C | C/A |
| MAFa in controls. | 0.04 | 0.11 |
| MAFa in all cases | 0.02 | 0.08 |
| MAFa in ER+ cases | 0.01 | 0.06 |
| MAFa in ER− cases | 0.03 | 0.09 |
| MAFa in 1000 Genomes Project EUR | 0.002 | 0.001 |
| Imputation information score | Genotyped | 0.991 |
| All cases vs. controlsd | ||
| OR (95% CI)b | 0.74 (0.57-0.96) | 0.82 (0.71-0.96) |
| P | 0.025 | 0.015 |
| Padj | 1.000 | 1.000 |
| ER+ cases vs. controlsd | ||
| OR (95% CI)b | 0.38 (0.24-0.61) | 0.53 (0.41-0.70) |
| P | 4.0E-05 | 3.6E-06 |
| Padj | 0.283 | 0.025 |
| ER− cases vs. controlsd | ||
| OR (95% CI)b | 0.69 (0.45-1.08) | 0.81 (0.62-1.06) |
| P | 0.103 | 0.119 |
| Padj | 1.000 | 1.000 |
CI, confidence interval; ER−, estrogen receptor-negative; ER+, estrogen receptor-positive; EUR, European; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
Minor allele frequency
Additive model with each SNP coded as 0, 1 or 2 copies of the minor allele, adjusting for age (10-year groups), study site and the first four eigenvectors from principal component analysis.
Bold P is significant at the defined cut point level (0.05/7,086 = 7.06E-06). Padj means P value after correction for multiple comparisons.
The numbers of controls and cases were 2,029, and 1,657 respectively. The numbers of ER+ patients and ER− patients were 403 and 374, respectively. ER status was not available for the remaining patients.